Are oral weight loss medications as effective as injections?

The myth worth setting down gently: 'pills never work as well as injections'

It is understandable where this idea comes from. For years, GLP-1 medicines existed only as injections, and the word 'pill' carried associations with older, less impressive weight-loss treatments. The assumption stuck. But it is worth revisiting now that a licensed oral GLP-1 option exists in the UK.

The Wegovy tablet is semaglutide (the same active molecule as in the Wegovy injection) but it reaches the bloodstream through a different route, assisted by an absorption enhancer called SNAC. That oral delivery process is less efficient than a subcutaneous injection; the body absorbs a smaller fraction of the dose. To compensate, the tablet's maintenance dose (25mg daily) is far higher by weight than the injection's 2.4mg weekly, but the net effect at the receptor level is comparable enough to produce real, clinically meaningful weight loss.

The OASIS 4 phase 3 trial (307 adults without diabetes, 64 weeks, reported at the time of the MHRA's June 2026 approval) found an average weight reduction of around 13.6% against 2.4% with placebo. Among participants who stuck fully to the treatment protocol, the average was closer to 16–17%. That is not nothing. It is also not quite the 15% seen with semaglutide 2.4mg injection in the STEP 1 trial, or the roughly 20% seen with tirzepatide 15mg in SURMOUNT-1, published in the New England Journal of Medicine. If you want to explore whether weight loss pills are as effective as injections, we look at that question in detail on its own dedicated page. The numbers tell a nuanced story rather than a simple yes or no.

Where the injection evidence is currently stronger

Weekly injections have had longer to accumulate evidence, and the scale of the trial programmes is larger. Tirzepatide (Mounjaro) was studied across thousands of adults in the SURMOUNT programme before NICE recommended it in December 2024. NICE's appraisal considered indirect comparisons across trials and found tirzepatide favoured over semaglutide 2.4mg, a finding reinforced by the direct head-to-head SURMOUNT-5 trial published in 2025. Semaglutide injection (Wegovy) has its own substantial evidence base dating back to 2021.

The injection also sidesteps the absorption problem. A subcutaneous dose bypasses the gut entirely, which is why the fasting requirement does not apply and bioavailability is high regardless of what you ate the night before. For people whose mornings are already complicated (shift workers, parents with young children, anyone whose first-thing-in-the-morning routine is unpredictable) that practical difference is worth thinking about. You can read more about how injection-based treatment works day to day on our weight-loss injection overview.

The evidence currently points to injections producing, on average, greater weight reduction. But 'greater average' in a population trial does not automatically mean 'better for this individual person'. A prescriber weighs up needle anxiety, lifestyle, adherence likelihood and medical history alongside the numbers, which is precisely why clinical assessment precedes any prescription.

What makes the oral route genuinely useful for some people

No needles, no sharps disposal, no refrigeration. The Wegovy tablet sits at room temperature, travels without an ice pack and leaves no injection-site reactions. For people with a significant aversion to needles (and that is a larger group than is often acknowledged) the prospect of a daily tablet changes the calculation entirely. A treatment someone can realistically take every day tends to outperform, in practice, one that causes dread.

The 30-minute fasting window before food is the main discipline the tablet asks for. Take it the moment you wake up with a small glass of plain water, set a timer, then get on with your morning. That is manageable for many people. The NHS semaglutide information page outlines the general taking instructions, and the full detail is in the Patient Information Leaflet that accompanies the medicine.

It is also worth noting that side effects in the OASIS 4 trial were predominantly gastrointestinal (nausea, diarrhoea, constipation) at a higher rate than with placebo, broadly similar in character to those reported with the injection. Most were mild to moderate and tended to ease as the body adjusted. For a fuller picture of the injection side-effect profile to compare against, our page on injection side effects covers that ground in detail. If you are curious about how the different injection options compare with each other before adding the tablet into the mix, the weight-loss injections overview is a useful starting point.

How a prescriber approaches the choice

Choosing between an oral medicine and an injection is not really a question of which is 'better' in the abstract, it is a clinical decision shaped by the individual. Eligibility criteria overlap but are not identical. Tirzepatide and the semaglutide injection both cover adults with a BMI of 30 or above, or from 27 with a weight-related health condition. The Wegovy tablet is licensed from BMI 30, with the same lower-threshold option for eligible BMI 27–29.9. Ethnic-background adjustments to BMI thresholds apply across all three under UK guidance. None of those numbers alone determines what a prescriber will recommend.

A prescriber also thinks about co-existing conditions, any medicines already being taken (including oral contraceptives, given that tirzepatide can affect pill absorption in the first weeks of treatment), and whether someone has already tried one route. If you are weighing up the options and want to understand the cost side of the picture, the injection pricing page gives factual market context. Our weight-loss treatments overview sets out what is currently available through nume. How effective weight-loss injections are is covered in its own dedicated page if you want to dig into the trial data more deeply. For any question about which route might suit your specific circumstances, the right place to start is a conversation with a clinician. You can do that through our free consultation, reviewed the same day by a real prescriber, not automated software.